Literature DB >> 34705180

Relationship of the Levels of microRNA Gene Methylation with the Level of Their Expression and Pathomorphological Characteristics of Breast Cancer.

E A Filippova1, I V Pronina1, S S Lukina1, T P Kazubskaya2, E A Braga1, A M Burdennyi3, V I Loginov1.   

Abstract

We studied the relationship of the levels of microRNA group expression and methylation with clinical and pathomorphological parameters of breast cancer and its immunohistochemical status. Quantitative methylation specific PCR analysis showed a significant (p<0.001) increase in the methylation level of 4 microRNA genes (MIR127, MIR129-2, MIR132, and MIR148A) and a significant (p<0.001) decrease for gene MIR375 relative to paired histologically normal tissue. Real-time PCR analysis revealed a significant (p≤0.001) decrease in the expression of 4 microRNAs (miR-127-5p, miR-129-5p, miR-132-3p, and miR-148a-3p) and a significant (p≤0.001) increase in the expression of miR-375-3p. A significant (rs=-0.6--0.7, p≤0.001) relationship between changes in the expression level of miR-129-5p, miR-132-3p, miR-148a-3p, and miR-375-3p and the levels of methylation of the corresponding genes in breast cancer was showed by using Spearman's rank correlation test. Analysis of the samples with consideration of the pathophysiological characteristics of the tumor revealed two significant markers of tumor progression: MIR129-2/miR-129-5p and MIR375/miR-375-3p. Both factors, the increase in the level of MIR129-2 methylation (p<0.001) and a decrease in the expression level of miR-129-5p (p<0.001), are significantly associated (p<0.001) with stage III/IV and the absence of HER2 expression. For MIR375/miR-375-3p, on the contrary, an association of low methylation level and enhanced expression with increased Ki-67 level (>30%, p<0.05) was revealed. These findings are of interest for understanding the mechanisms of breast cancer development and can provide the basis for the diagnosis and prognosis of the course of this disease. Moreover, the revealed features can be useful for adjusting the course of treatment with consideration of the pathophysiological characteristics of the tumor.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  HER2neu; breast cancer; expression; methylation; microRNA

Mesh:

Substances:

Year:  2021        PMID: 34705180     DOI: 10.1007/s10517-021-05312-2

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  9 in total

Review 1.  Dysregulation of the epigenome in human breast cancer: contributions of gene-specific DNA hypermethylation to breast cancer pathobiology and targeting the breast cancer methylome for improved therapy.

Authors:  Rupninder Sandhu; J Devon Roll; Ashley G Rivenbark; William B Coleman
Journal:  Am J Pathol       Date:  2014-12-23       Impact factor: 4.307

2.  Epigenetic silencing of miR-200c in breast cancer is associated with aggressiveness and is modulated by ZEB1.

Authors:  Valentina Damiano; Giulia Brisotto; Silvia Borgna; Alessandra di Gennaro; Michela Armellin; Tiziana Perin; Michela Guardascione; Roberta Maestro; Manuela Santarosa
Journal:  Genes Chromosomes Cancer       Date:  2016-11-01       Impact factor: 5.006

3.  Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.

Authors:  Maria Panagopoulou; Makrina Karaglani; Ioanna Balgkouranidou; Eirini Biziota; Triantafillia Koukaki; Evaggelos Karamitrousis; Evangelia Nena; Ioannis Tsamardinos; George Kolios; Evi Lianidou; Stylianos Kakolyris; Ekaterini Chatzaki
Journal:  Oncogene       Date:  2019-01-14       Impact factor: 9.867

4.  A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis.

Authors:  Kirsten Hattermann; H Maximilian Mehdorn; Rolf Mentlein; Susann Schultka; Janka Held-Feindt
Journal:  Anal Biochem       Date:  2008-03-14       Impact factor: 3.365

5.  Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.

Authors:  Vitaly I Loginov; Irina V Pronina; Alexey M Burdennyy; Elena A Filippova; Tatiana P Kazubskaya; Dmitry N Kushlinsky; Dmitry O Utkin; Dmitry S Khodyrev; Nikolay E Kushlinskii; Alexey A Dmitriev; Eleonora A Braga
Journal:  Gene       Date:  2018-04-06       Impact factor: 3.688

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Differentially expressed microRNAs in postpartum breast cancer in Hispanic women.

Authors:  José L Muñoz-Rodríguez; Lukas Vrba; Bernard W Futscher; Chengcheng Hu; Ian K Komenaka; Maria Mercedes Meza-Montenegro; Luis Enrique Gutierrez-Millan; Adrian Daneri-Navarro; Patricia A Thompson; Maria Elena Martinez
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

8.  Biomarker discovery to improve prediction of breast cancer survival: using gene expression profiling, meta-analysis, and tissue validation.

Authors:  Liwei Meng; Yingchun Xu; Chaoyang Xu; Wei Zhang
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

9.  Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.

Authors:  Elizabeth Poli; Jing Zhang; Chika Nwachukwu; Yonglan Zheng; Babatunde Adedokun; Olufunmilayo I Olopade; Yoo-Jeong Han
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

  9 in total
  1 in total

1.  miR-127-5p Targets JAM3 to Regulate Ferroptosis, Proliferation, and Metastasis in Malignant Meningioma Cells.

Authors:  Jing Zhang; Zang Liu; Yipeng Dong
Journal:  Dis Markers       Date:  2022-07-02       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.